DTC
APLS

Deep Track Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Deep Track Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,532,374
Closed -$182M – 70
2026
Q1 		$182M Sell
4,532,374
-3,217,626
-42% -$69.3M 2.98% 8
2025
Q4 		$195M Sell
7,750,000
-250,382
-3% -$5.87M 3.47% 9
2025
Q3 		$181M Buy
8,000,382
+1,000,382
+14% +$23.3M 5.05% 5
2025
Q2 		$121M Buy
7,000,000
+2,000,000
+40% +$37M 3.89% 9
2025
Q1 		$109M Buy
5,000,000
+725,079
+17% +$20M 3.54% 9
2024
Q4 		$136M Sell
4,274,921
-125,733
-3% -$3.78M 5.09% 5
2024
Q3 		$127M Buy
4,400,654
+1,900,654
+76% +$70.4M 4.03% 4
2024
Q2 		$95.9M Buy
2,500,000
+1,500,000
+150% +$67.9M 2.86% 12
2024
Q1 		$58.8M Buy
+1,000,000
New +$63.7M 1.68% 24

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Deep Track Capital's APLS Position: Q2 2026 in Review

Deep Track Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 4,532,374 shares — an estimated $182M sold.

Deep Track Capital first reported a position in APLS in Q1 2024 and held it in 9 quarters. The position peaked at $195M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Deep Track Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Deep Track Capital sold 4,532,374 Apellis Pharmaceuticals shares in Q2 2026, an estimated $182M.
  • Deep Track Capital first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • Deep Track Capital's Apellis Pharmaceuticals position peaked at $195M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.